Market Place
Sourcing Support
All News #Library
Biotech
Zura Bio Reveals 2025 Financials And Corporate Updates
19 Mar 2026 //
PHARMIWEB
Zura Bio Unveils TibuSURE Design for Dual IL-17A in SSC Congress
05 Mar 2026 //
PHARMIWEB
Zura Bio To Participate In Upcoming Investor Conferences
02 Mar 2026 //
PHARMIWEB
Zura Bio Closes $144M Offering as Underwriters Exercise Option
27 Feb 2026 //
PHARMIWEB
Zura Bio Prices $125M Public Offering Of Class A Shares
25 Feb 2026 //
PHARMIWEB
Zura Bio Announces Offering of Class A Shares and Pre-Funded
24 Feb 2026 //
BUSINESSWIRE
Zura Bio to Participate in the Guggenheim Emerging Outlook
04 Feb 2026 //
PHARMIWEB
Zura Bio Appoints Immunology Leader Sandeep Kulkarni, MD, as CEO
21 Jan 2026 //
BUSINESSWIRE
Zura Bio Reports Business Updates And Outlook For 2026
12 Jan 2026 //
PHARMIWEB
Zura Bio Unveils Q3 2025 Financials & Corporate Developments
13 Nov 2025 //
BUSINESSWIRE
Zura Bio Reports Q2 2025 Results and Corporate Updates
14 Aug 2025 //
BUSINESSWIRE
Zura Bio`s Phase 2 TibuSHIELD Study for Hidradenitis Suppurativa
20 May 2025 //
BUSINESSWIRE
Zura Bio Launches Phase 2 Tibusure Study for Systemic Sclerosis
23 Dec 2024 //
BUSINESSWIRE
Zura Bio to Present at Piper Sandler 36th Annual Health Conference
25 Nov 2024 //
BUSINESSWIRE
Zura Bio Submits Protocol to FDA for Ph 2 in Systemic Sclerosis
14 Nov 2024 //
BUSINESSWIRE
Zura Bio Reports Q2 2024 Results And Recent Business Highlights
13 Aug 2024 //
BUSINESSWIRE
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
14 Jun 2024 //
BUSINESSWIRE
Zura`s Tibulizumab Potential In Sjogren`s, RA At EULAR 2024
03 Jun 2024 //
BUSINESSWIRE
Zura Bio Announces $80 M Financing and the Licensing of Tibulizumab (ZB-106)
27 Apr 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.